Edgar Filing: Duliege Anne-Marie - Form 4

Duliege An	nne-Marie									
Form 4										
March 22, 2	2019									
FORM					CHANCE		т	PPROVAL		
	UNITED		Washington,			COMMISSION	OMB Number:	3235-0287		
if no lo subject Section Form 4	to SIAIE 16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Expires: Estimated burden hou response	urs per		
Form 5 obligati may co <i>See</i> Inst 1(b).	ntinue. Frida put	(a) of the Publi		ding Cor	npany Act	nge Act of 1934, of 1935 or Sectio 940	on			
(Print or Type	e Responses)									
1. Name and Address of Reporting Person <u>*</u> Duliege Anne-Marie			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]			 5. Relationship of Reporting Person(s) to Issuer C (Check all applicable) 				
	IARMACEUTICA VETERANS	(Mor	ate of Earliest Tr nth/Day/Year) 20/2019	ransaction		Director X Officer (giv below) EVP & 0		% Owner her (specify Officer		
	Filed			If Amendment, Date Original led(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
SOUTH S. FRANCIS	AN CO, CA 94080					Person		eporting		
(City)	(State)	(Zip)	Table I - Non-I	Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea	Code	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code V	Amount	(D) Price	(Instr. 3 and 4)				
Reminder: Re	eport on a separate line	e for each class of	securities benef	ficially ow	ned directly o	or indirectly.				
						pond to the colle ained in this form		SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

number.

required to respond unless the form displays a currently valid OMB control

Edgar Filing: Duliege Anne-Marie - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration E (Month/Day	Date	7. Title and <i>J</i> Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 4.49	03/20/2019		А	75,000	<u>(1)</u>	01/24/2028	Common Stock	75,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Duliege Anne-Marie			EVP &			
RIGEL PHARMACEUTICALS, INC.			Chief			
1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO, CA 94080			Medical Officer			
5001Π SAN FRANCISCO, CA 94080			Unicer			

Signatures

/s/ Dolly Vance (Attorney-in-Fact)

03/22/2019 Date

<u>**</u>Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) On January 24, 2018, the reporting person was granted a performance based option to purchase 75,000 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.